Stryker Co. (NYSE:SYK) Shares Purchased by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund raised its holdings in shares of Stryker Co. (NYSE:SYK) by 0.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 29,405 shares of the medical technology company’s stock after buying an additional 54 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Stryker were worth $10,587,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Dunhill Financial LLC grew its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter worth approximately $33,000. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the 3rd quarter worth approximately $36,000. Finally, Activest Wealth Management acquired a new position in shares of Stryker in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.3 %

Shares of Stryker stock opened at $391.54 on Thursday. The business’s fifty day moving average price is $379.42 and its two-hundred day moving average price is $370.37. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $149.40 billion, a P/E ratio of 50.46, a PEG ratio of 2.93 and a beta of 0.96. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 EPS. As a group, research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research report on Wednesday, January 29th. Royal Bank of Canada raised their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.